These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 9368023)
21. Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Rittenhouse HG; Finlay JA; Mikolajczyk SD; Partin AW Crit Rev Clin Lab Sci; 1998 Aug; 35(4):275-368. PubMed ID: 9759557 [TBL] [Abstract][Full Text] [Related]
22. Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing. Denmeade SR; Lövgren J; Khan SR; Lilja H; Isaacs JT Prostate; 2001 Jul; 48(2):122-6. PubMed ID: 11433422 [TBL] [Abstract][Full Text] [Related]
23. Assessment of the trypsin-like human prostatic kallikrein, also known as hK2, in the seminal plasma of infertile men: respective contributions of an ELISA procedure and of Western blotting. Tremblay RR; Coulombe E; Cloutier S; Brunet C; Deperthes D; Frenette G; Dubé JY J Lab Clin Med; 1998 Apr; 131(4):330-5. PubMed ID: 9579386 [TBL] [Abstract][Full Text] [Related]
24. Purification of enzymatically active kallikrein hK2 from human seminal plasma. Frenette G; Deperthes D; Tremblay RR; Lazure C; Dubé JY Biochim Biophys Acta; 1997 Feb; 1334(1):109-15. PubMed ID: 9042371 [TBL] [Abstract][Full Text] [Related]
25. Human kallikrein 2 (hK2), but not prostate-specific antigen (PSA), rapidly complexes with protease inhibitor 6 (PI-6) released from prostate carcinoma cells. Saedi MS; Zhu Z; Marker K; Liu RS; Carpenter PM; Rittenhouse H; Mikolajczyk SD Int J Cancer; 2001 Nov; 94(4):558-63. PubMed ID: 11745444 [TBL] [Abstract][Full Text] [Related]
26. Effects of secondary interactions on the kinetics of peptide and peptide ester hydrolysis by tissue kallikrein and trypsin. Fiedler F Eur J Biochem; 1987 Mar; 163(2):303-12. PubMed ID: 3643848 [TBL] [Abstract][Full Text] [Related]
27. Substrate specificity of human kallikrein 2 (hK2) as determined by phage display technology. Cloutier SM; Chagas JR; Mach JP; Gygi CM; Leisinger HJ; Deperthes D Eur J Biochem; 2002 Jun; 269(11):2747-54. PubMed ID: 12047384 [TBL] [Abstract][Full Text] [Related]
28. Association of kallikrein expression in nipple aspirate fluid with breast cancer risk. Sauter ER; Lininger J; Magklara A; Hewett JE; Diamandis EP Int J Cancer; 2004 Feb; 108(4):588-91. PubMed ID: 14696124 [TBL] [Abstract][Full Text] [Related]
29. Protein products of the rat kallikrein gene family. Substrate specificities of kallikrein rK2 (tonin) and kallikrein rK9. Moreau T; Brillard-Bourdet M; Bouhnik J; Gauthier F J Biol Chem; 1992 May; 267(14):10045-51. PubMed ID: 1315752 [TBL] [Abstract][Full Text] [Related]
30. Identification of a novel complex between human kallikrein 2 and protease inhibitor-6 in prostate cancer tissue. Mikolajczyk SD; Millar LS; Marker KM; Rittenhouse HG; Wolfert RL; Marks LS; Charlesworth MC; Tindall DJ Cancer Res; 1999 Aug; 59(16):3927-30. PubMed ID: 10463585 [TBL] [Abstract][Full Text] [Related]
32. Pro-rat atrial natriuretic peptide-mimicking peptides as substrates for rat kallikreins rK2 (tonin) and rK9. Moreau T; Brillard-Bourdet M; Chagas J; Gauthier F Biochim Biophys Acta; 1995 Jun; 1249(2):168-72. PubMed ID: 7599170 [TBL] [Abstract][Full Text] [Related]
33. Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer. Janssen S; Jakobsen CM; Rosen DM; Ricklis RM; Reineke U; Christensen SB; Lilja H; Denmeade SR Mol Cancer Ther; 2004 Nov; 3(11):1439-50. PubMed ID: 15542783 [TBL] [Abstract][Full Text] [Related]
34. alpha2-macroglobulin and C1-inactivator are plasma inhibitors of human glandular kallikrein. Heeb MJ; España F Blood Cells Mol Dis; 1998 Dec; 24(4):412-9. PubMed ID: 9851894 [TBL] [Abstract][Full Text] [Related]
35. Mapping the active sites of bovine thrombin, factor IXa, factor Xa, factor XIa, factor XIIa, plasma kallikrein, and trypsin with amino acid and peptide thioesters: development of new sensitive substrates. McRae BJ; Kurachi K; Heimark RL; Fujikawa K; Davie EW; Powers JC Biochemistry; 1981 Dec; 20(25):7196-206. PubMed ID: 6976185 [TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical study suggesting a complementary role of kallikreins hK2 and hK3 (prostate-specific antigen) in the functional analysis of human prostate tumors. Tremblay RR; Deperthes D; Têtu B; Dubé JY Am J Pathol; 1997 Feb; 150(2):455-9. PubMed ID: 9033261 [TBL] [Abstract][Full Text] [Related]
37. Structural investigation of the alpha-1-antichymotrypsin: prostate-specific antigen complex by comparative model building. Villoutreix BO; Lilja H; Pettersson K; Lövgren T; Teleman O Protein Sci; 1996 May; 5(5):836-51. PubMed ID: 8732755 [TBL] [Abstract][Full Text] [Related]
38. Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3. Réhault S; Monget P; Mazerbourg S; Tremblay R; Gutman N; Gauthier F; Moreau T Eur J Biochem; 2001 May; 268(10):2960-8. PubMed ID: 11358513 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of the extent of the binding site in human tissue kallikrein by synthetic substrates with sequences of human kininogen fragments. Del Nery E; Chagas JR; Juliano MA; Prado ES; Juliano L Biochem J; 1995 Nov; 312 ( Pt 1)(Pt 1):233-8. PubMed ID: 7492318 [TBL] [Abstract][Full Text] [Related]
40. Mutant recombinant serpins as highly specific inhibitors of human kallikrein 14. Felber LM; Kündig C; Borgoño CA; Chagas JR; Tasinato A; Jichlinski P; Gygi CM; Leisinger HJ; Diamandis EP; Deperthes D; Cloutier SM FEBS J; 2006 Jun; 273(11):2505-14. PubMed ID: 16704423 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]